BioDiscovery, Inc

5155 Rosecrans Avenue, Suite 310
Hawthorne,  CA  90250

United States
Phone: 310-414-8111
http://www.biodiscovery.com
  • Booth: 317

Profile

BioDiscovery develops, markets and sells advanced software solutions for the analysis of data from high-throughput microarray and next-generation sequencing technologies. BioDiscovery provides modular software packages built for power, versatility, and efficiency spanning image analysis, microarray data processing, and advanced analysis of CNV, expression, and methylation data. These products empower Biologists and Geneticists with sophisticated, yet highly usable tools to analyze and interpret their data and draw meaningful conclusions.


 Press Releases

  • BioDiscovery’s Nexus Copy Number software is a leading solution for researchers across the globe for analysis of sequence and structural variation. The software is built on over a decade of research, design, and development in the genomics field and offers unique and user-friendly features to advance research studies.

     

    A cutting-edge feature in Nexus Copy Number 8.0 is derivation of copy number from next-generation sequencing results. The new algorithm for obtaining CNVs from sequencing results provides results comparable to those from microarrays and detects copy number from whole-exome sequencing (WES), whole-genome sequencing (WGS), and targeted NGS panels. In concert with extraction of CNVs, the algorithm also identifies regions of Loss of Heterozygosity (LOH) and Allelic Imbalances (AI), a unique feature not found in other similar tools. For researchers performing NGS-based studies, the ability to also extract CNV and LOH events from the same data being used to generate SNVs offers a great benefit at almost no additional cost. Concurrent analysis of copy number, allelic events, sequence variants and gene regulation information as possible with Nexus Copy Number provides a truly integrated and comprehensive view of genomic alterations.

     

    Nexus Copy Number version 8.0 also encompasses expanded gene regulation support with analysis and visualization of gene expression results on single samples alongside copy number and sequence variations allowing identification of genes highly correlated among the different modalities. Platform independence reigns here as well with support for data from different vendors and platforms (e.g. RNASeq and mRNA/miRNA arrays including support for the Affymetrix GeneChip HTA 2.0, new in version 8.0).

     

    BioDiscovery’s platform-independent software packages provide a complete spectrum of data analysis solutions for gene expression (RNASeq, mRNA, miRNA) and copy number and sequence variation from microarray and NGS (WES, WGS, targeted panels) technologies. Nexus Copy Number is a user-friendly and robust software with specialized cancer specific tools and algorithms and the capability to handle large volumes of data. 

     

    Conference attendees at the ACMG Annual Meeting have the opportunity to visit BioDiscovery at booth #317 to analyze and interpret their own array and NGS data through Nexus Copy Number. To learn more about Nexus Copy Number, please visit http://www.biodiscovery.com/nexus-copy-number/.

  • BioDiscovery, Inc. a leader in innovative genomic data analysis software recently released NxClinical 2.1, a comprehensive software solution for molecular genetics and cytogenomics labs. NxClinical is a flexible, platform-agnostic database solution for efficient analysis, interpretation, and reporting of genomic variations and is rapidly being implemented by both hospital and independent clinical reference laboratories. CombiMatrix, a national reference laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders and Lurie Children’s Hospital in Chicago, one of the top pediatric providers in the Midwest and a recognized leader in research and education have recently transitioned to using NxClinical 2.1 software.

    “The functionality of NxClinical has allowed us to simplify and standardize our interpretation of CNVs across our group of Directors.  This significantly reduces the time required to review the 10+ variants identified per genome,” said Lawrence Jennings, MD, PhD, Director, HLA and Molecular Diagnostic Labs. The genetics labs at Lurie Children’s Hospital offers cytogenetic and molecular testing for diagnosis of inherited disorders and also offers testing for transplantation. CombiMatrix, a national reference laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders also recently adopted NxClinical 2.1.

    “The different sample types necessitate specific analytical, review and reporting workflow requirements. Adoption of the NxClinical software has provided an efficient and secure workflow for our data batch loading and processing at our high volume clinical laboratory,” said Karine Hovanes, PhD, FACMG, Vice President of Scientific Advancement and Laboratory Director. “Its improved features support various workflow designations for different test types allowing us to analyze and store the data within each workflow. Moreover, as a result of an easy and updated access to the public reference databases as well as our own database of historical cases, the interpretation of chromosomal microarray data is extremely efficient and consistent.”

    NxClinical 2.1 is a multi-user system with a central database easily accessible from anywhere. Using standardized and automated processes, NxClinical increases overall productivity and consistency in the entire workflow. In version 2.1, software improvements include the incorporation of additional databases such as OMIM® (Online Mendelian Inheritance in Man) and ClinVar, ISCN (International System for Human Cytogenetic Nomenclature) notation in reports, and HPO (Human Phenotype Ontology) terms for samples enabling scoring of variants based on genes implicated in specific phenotypes, all contributing to further speeding up of event interpretation.

    Conference attendees at the ACMG Annual Meeting have the opportunity to visit BioDiscovery at booth #317 to analyze and interpret their own data through NxClinical. To learn more about NxClinical please visit http://www.biodiscovery.com/nxclinical/.

Registration for ACMG 2017

Register will open in October 2016

March 21 - 25, 2017
Phoenix Convention Center
Phoenix, Arizona

Hotel Reservations

Reserve your room early to get the best choice.